Medical devices, healthcare technology and the business of care
PMA approval · P240033

LungFX device

Lung Bioengineering, Inc. · Decision date Jun 22, 2026

FDA DECISIONP240033

What did the FDA approve?

FDA records P240033 as an original PMA application. The recorded decision is approval, dated Jun 22, 2026.

FDA approval order statement

This device (LungFX) is indicated for centralized, ex vivo (outside the body) evaluation of deceased-donor lungs (single and double) that cannot be placed for transplantation by an Organ Procurement Organization (OPO) with any of the matched candidates if using direct-to-recipient procurement and preservation procedures. LungFX provides normothermic perfusion and ventilation of procured donor lungs initially stored with cold static preservation solution.LungFX is intended to allow for re-assessment, in a controlled environment, of procured donor lungs suitability for transplantation into male and female patients aged 18 years or older with end-stage lung disease awaiting first time (double or single) lung transplantation. Lungs accepted for transplantation after LungFX require a second period of storage with cold static preservation solution, and cumulative preservation time of transplanted lungs is not intended to exceed 20 hours.
Regulatory pathway
Original PMA
Clinical specialty
Gastroenterology, Urology
Decision date
Jun 22, 2026

FDA source record

Regulatory record facts

Identifier
P240033
Regulatory pathway
Premarket approval application
Product code
PHO
Decision code
APPR
Decision date
Jun 22, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Normothermic preservation system for transplantation of initially unacceptable donor lungs.

Product code
PHO
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P240033 received

    Application receipt date recorded by FDA.

  2. P240033 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P240033. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240033

Product / regulatory recordCompanyPathwayDecision dateSource
LungFX DeviceP240033/S001
Lung Bioengineering, Inc.PMA supplementOct 16, 2026FDA
LungFX DeviceP240033/S002
Lung Bioengineering, Inc.PMA supplementOct 16, 2026FDA

Explore the linked device profile

Other records with product code PHO

Product / regulatory recordCompanyPathwayDecision dateSource
Traferox Technologies, Inc.PMA supplementOct 30, 2026FDA
Traferox Technologies, Inc.PMA supplementOct 30, 2026FDA
Xvivo Perfusion, Inc.PMA supplementSep 16, 2026FDA
Traferox Technologies, Inc.PMA approvalJul 15, 2026FDA
Xvivo Perfusion, Inc.PMA approvalApr 26, 2019FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Lung Bioengineering, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Lb1 Bldg., 1015 Spring St., Silver Spring, MD, 20910

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records